Guyer Charles Greg's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Nov 14, 2024
- Accession no.
- 0001048477-24-000154
- Filed
- Nov 14, 2024
- Trade date
- Oct 31-Nov 12, 2024
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $350.3K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Guyer Charles GregCIK 0001811096 | Officer (EVP, Chief Technical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 31, 2024 | Common Stock | AGrant or awardAcquired | +55 | $56.01 | +$3,080.55 | 74,187 | Direct | |
| Nov 12, 2024 | Common Stock | SSaleDisposed | −5,278 | $66.37 | −$350,300.86 | 68,909 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.